Patients with inflammatory arthritis would benefit from vaccination against herpes zoster, with the Shingrix vaccine showing a crude effectiveness of 50%.

The US Food and Drug Administration (FDA) has approved GSK's Shingrix vaccine (recombinant zoster vaccine or RZV) in a ...

This new Shingrix vaccine presentation eliminates the need for reconstitution, simplifying the administration process for ...

The U.S. Food and Drug Administration has approved GSK's prefilled syringe presentation of Shingrix (zoster vaccine ...

The Food and Drug Administration (FDA) has approved a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

Some immunizations may be quietly protecting us from cognitive decline. How the medicine might do that is a mystery scientists are desperate to solve. A new study on two vaccines for older adults ...

Shingrix's manufacturer, GlaxoSmithKline, didn't anticipate it would be so popular when it first hit the market. In the first six months of 2018 alone, more doses of Shingrix were administered in ...

Shingrix is also better than Zostavax in preventing nerve pain that continues after a shingles rash has cleared -- about 90 percent effective versus 65 percent effective, the briefing stated.

Shingrix is contraindicated for immunocompromised adults with a history of severe allergies, anaphylaxis, or those with prior vaccine-related adverse reactions, according to the vaccine's label.

Shingrix, the new shingles vaccine, is over 90 percent effective in preventing the painful viral infection Julie Mazziotta is the Senior Sports Editor at PEOPLE, covering everything from the NFL ...

Shingrix's efficacy rate is more than 90%, according to GSK. Experts recommend anyone who wants Shingrix to get on the waitlist at a pharmacy, clinic or doctor's office. More from CBS News.

The FDA has approved a prefilled syringe option of Shingrix which will streamline administration of GSK’s herpes zoster ...